Antimalarial and Covid 19 in Rheumatoid Arthritis

Completed

• Conditions: Rheumatoid Arthritis
• Interventions: Drug: Hydroxychloroquine

• Registration Number: NCT04389320
• Lead Sponsor: Assiut University

Brief Summary

The antimalarial agent hydroxychloroquine(HCQ) have been used widely used for the treatment of rheumatoid arthritis and systemic lupus erythematosus. These compounds lead to improvement of clinical and laboratory parameters, but their slow onset of action differ them from glucocorticoids and nonsteroidal antiinflammatory agents.

Among rheumatic diseases, the primary role of HCQ is in the management of articular and skin manifestations of systemic lupus erythematosus (SLE) and the treatment of mild to moderately active rheumatoid arthritis (RA).

Detailed Description

The antimalarial agent hydroxychloroquine(HCQ) have been used widely used for the treatment of rheumatoid arthritis and systemic lupus erythematosus.(1) . These compounds lead to improvement of clinical and laboratory parameters, but their slow onset of action differ them from glucocorticoids and nonsteroidal antiinflammatory agents.

Among rheumatic diseases, the primary role of HCQ is in the management of articular and skin manifestations of systemic lupus erythematosus (SLE) and the treatment of mild to moderately active rheumatoid arthritis (RA).

It is difficult to carefully evaluate the onslaught of information that has emerged regarding potential COVID-19 therapies within a few months' time in early 2020. A brief but detailed approach regarding how to evaluate resulting evidence of a study has been presented by F. Perry Wilson, MD, MSCE. By using the example of a case series of patients given hydroxychloroquine plus azithromycin, he provides clinicians with a quick review of critical analyses.

Study Timeline

• Study Start: 2020-03-15
• Status Verified: 2020-05
• Primary Completion: 2020-05-01
• Study Completion: 2020-05-01
• Study First Submitted: 2020-05-11
• Study First Submitted QC: 2020-05-13
• Last Update Submitted: 2020-05-13
• Study First Posted: 2020-05-15
• Last Update Posted: 2020-05-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• rheumatoid arthritis recieving hydroxychloroquine chest infection

Exclusion Criteria

• patients not used hydroxychloroquine

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Rheumatoid patients receiving hydroxychloroquine	Hydroxychloroquine	immunoglobulin analyses of covid 19 virus in patients already on hydroxychloroquine and relation to clinical presentation and genetics

Primary Outcome Measures

Name	Time	Method
immunoglobulin mesurement	1 month	serum level

Trial Locations

Locations (1)

Manal Hassanien; 🇪🇬 Assiut, Yes, Egypt